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Abstract
Objective:  This  study  aims  to  investigate  the  role  of  metabolic  syndrome  (MetS)  and  the
hypertriglyceridemic-waist  (HW)  phenotype  in  determining  cardiometabolic  risk  factors  and
elevated liver  enzymes  in  a  national  sample  of  Iranian  pediatric  population.
Method:  This  nationwide  study  was  conducted  in  the  framework  of  the  third  survey  of  a  surveil-
lance program.  Students,  aged  10--18  years,  were  recruited  from  27  provinces  in  Iran.  The
prevalence  of  cardiometabolic  risk  factors  was  compared  in  students  with  and  without  HW  and
MetS. The  association  of  HW  with  different  cardiometabolic  risk  factors  was  determined.
Results:  The  mean  age  of  studied  population  was  14.73  ±  2.41  years.  Prevalence  of  HW  and
MetS was  3.3%  and  4%,  respectively.  Sixty-nine  (71.1%)  participants  with  HW  had  MetS.  The
prevalence  of  obesity,  elevated  systolic  blood  pressure,  hypercholesterolemia,  and  elevated
alanine aminotransaminase  (ALT)  was  signiﬁcantly  higher  in  subjects  with  HW  phenotype  and
MetS than  in  their  peers  (p  <  0.05).  A  signiﬁcant  association  was  observed  between  HW  and
elevated  levels  of  cholesterol  and  ALT,  as  well  as  between  obesity  and  low  HDL-C  (p  <  0.05).
Conclusions:  The  current  ﬁndings  serve  as  complementary  evidence  to  previous  studies,  which
have been  mainly  conducted  among  adults,  suggesting  that  the  HW  phenotype  is  associated  with
cardiometabolic  risk  factors,  especially  with  elevated  cholesterol  and  ALT.  The  authors  propose
that, in  primary  care  settings  and  in  large  epidemiological  studies,  the  measurement  of  all  MetS
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components  can  be  replaced  by  studying  HW  as  a  screening  tool  for  identifying  children  at  high
risk for  cardiometabolic  disorders.
©  2016  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Sociedade  Brasileira  de  Pediatria.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Associac¸ão  do  fenótipo  de  cintura  hipertrigliceridêmica  com  enzimas  hepáticas
e  fatores  de  risco  cardiometabólico  em  adolescentes:  o  estudo  CASPIAN-III
Resumo
Objetivo:  Este  estudo  visa  investigar  o  desempenho  da  síndrome  metabólica  e  do  fenótipo
de cintura  hipertrigliceridêmica  (CH)  na  determinac¸ão  de  fatores  de  risco  cardiometabólico  e
enzimas hepáticas  elevadas  em  uma  amostra  nacional  da  populac¸ão  pediátrica  iraniana.
Método: Este  estudo  nacional  foi  realizado  na  estrutura  da  terceira  pesquisa  de  um  programa
de vigilância.  Foram  recrutados  alunos  de  10-18  anos  de  27  províncias  do  Irã.  A  prevalência  de
fatores de  risco  cardiometabólico  foi  comparada  em  alunos  com  e  sem  CH  e  SM.  Foi  determinada
a associac¸ão  da  CH  com  diferentes  fatores  de  risco  cardiometabólico.
Resultados:  A  média  de  idade  da  populac¸ão  estudada  foi  de  14,73  ±  2,41  anos.  A  prevalência  de
CH e  SM  foi  de  3,3%  e  4%,  respectivamente.  69  (71,1%)  dos  participantes  com  CH  apresentaram
SM. A  prevalência  de  obesidade,  pressão  arterial  sistólica  elevada,  hipercolesterolemia  e  ALT
elevada foi  signiﬁcativamente  maior  em  meninos  e  meninas  com  fenótipo  CH  e  SM  que  em  seus
outros pares  (P  <  0,05).  A  associac¸ão  de  CH  foi  signiﬁcativa  com  elevados  níveis  de  colesterol  e
ALT, bem  como  obesidade  e  HDL-C  baixo  (P  <  0,05).
Conclusões:  Os  achados  atuais  servem  de  evidência  complementar  de  estudos  anteriores,  con-
duzidos principalmente  com  adultos,  e  sugerem  que  o  fenótipo  CH  está  associado  a  fatores
de risco  cardiometabólico,  principalmente  com  colesterol  e  ALT  altos.  Propomos  que,  em
ambientes de  cuidados  básicos  e  em  grandes  estudos  epidemiológicas,  a  medic¸ão  de  todos
os componentes  de  SM  possa  ser  substituída  pelo  estudo  da  CH  como  ferramenta  de  triagem
para identiﬁcar  crianc¸as  com  alto  risco  de  apresentarem  distúrbios  cardiometabólicos.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Pediatria.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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Introduction
Non-communicable  diseases,  the  leading  cause  of  both
mortality  and  morbidity  in  most  populations,  origin  from
early  life.1 A  clustering  of  risk  factors  increases  the
risk  of  chronic  diseases.  Different  combinations  of  risk
factors  are  suggested  to  identify  children  at  risk  for  non-
communicable  diseases.  Metabolic  syndrome  (MetS)  is  one
of  these  combinations  that  has  been  well  documented  as
a  predisposing  factor  for  most  chronic  diseases.  However,
examining  all  ﬁve  components  of  MetS  in  large  population-
based  studies  is  difﬁcult  and  costly.  Moreover,  there  is
substantial  controversy  between  the  various  deﬁnitions
of  MetS  and  the  clinical  screening  parameters  and  cut-
off  points  proposed  by  different  organizations.2 Currently.
there  is  no  universally  accepted  deﬁnition  for  MetS  in  the
pediatric  age  group.  Therefore,  simple  screening  indexes
should  be  developed  for  population-based  screening  stud-
ies.  Hypertriglyceridemic  waist  (HW),  i.e.  the  coexistence
of  abdominal  adiposity  and  hypertriglyceridemia,  is  a  sim-
ple  combination  of  risk  factors.3--5 Both  MetS  and  HW  were
found  to  be  associated  with  increased  cardiometabolic
risk,  including  insulin  resistance,  atherogenic  dyslipidemia,
hypertension,  endothelial  dysfunction,  low-grade  inﬂamma-
tion,  and  impaired  hemostasis.6,7
Lemieux  et  al.3 were  the  ﬁrst  authors  to  docu-
ment  the  association  of  HW  phenotype  with  increased
s
S
dardiometabolic  risk  in  adult  men.  In  particular,  the  HW
henotype  was  associated  with  the  atherogenic  triad  of
yperinsulinemia,  elevated  concentrations  of  apolipopro-
ein  B.  and  small,  dense  low-density  lipoprotein  cholesterol
LDL-C)  particles.  Further  studies  conﬁrmed  the  association
f  HW  with  cardiometabolic  risk  factors8--10;  however,  most
f  these  studies  have  been  conducted  in  adult  populations.
A  growing  body  of  evidence  suggests  the  association
f  liver  function  tests  with  MetS  components.  This  cor-
elation  has  been  demonstrated  even  for  children  and
dolescents.11,12 There  is  limited  experience  on  the  asso-
iation  of  HW  phenotype  with  cardiometabolic  risk  factors
nd  elevated  liver  enzymes  in  the  pediatric  age  group.
This  study  aimed  to  compare  the  frequency  of  car-
iometabolic  risk  factors  and  elevated  liver  enzymes  in
hildren  and  adolescence  with  HW  phenotype  and  MetS,  to
nvestigate  the  performance  of  the  HW  phenotype  in  deter-
ining  the  aforementioned  risk  factors  in  this  population.
ethods
his  cross-sectional  study  was  conducted  in  the  frame-urveillance  program  entitled  Childhood  and  Adolescence
urveillance  and  PreventIon  of  Adult  Non-communicable
isease  (CASPIAN-III)  study.  Its  detailed  methodology  has
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een  previously  published13;  it  will  be  brieﬂy  described
erein.
This  project  was  approved  by  the  Research  Ethics
ommittees  and  other  relevant  national  regulatory  orga-
izations.  A  written  informed  consent  and  oral  assent
ere  obtained  from  parents  and  students,  respectively.  The
roject  team  members  were  trained,  and  a  comprehensive
peration  manual  was  given  to  them.  The  Data  and  Safety
onitoring  Board  of  the  project  has  taken  into  account
or  different  levels  of  quality  control.  A  group  of  external
valuators  and  supervisors  assessed  the  performance  of  the
ersonnel,  and  monitored  and  calibrated  the  equipment.
The  present  study  included  5625  students  aged  10--18
ears,  recruited  by  multistage  random  cluster  sampling  from
rban  and  rural  areas  of  27  provinces  in  Iran.  For  the  present
tudy,  eligible  schools  were  randomly  selected  from  the
ist  of  schools,  which  were  stratiﬁed  according  to  database
rom  the  Iranian  Ministry  of  Education.  Students  were  also
elected  randomly  from  each  selected  school.  Those  stu-
ents  who  had  any  chronic  disease  or  received  medications
ere  not  included  in  the  survey.
hysical  examination
 team  of  trained  physicians,  nurses,  and  healthcare  profes-
ionals  conducted  the  physical  examination  under  standard
rotocols  and  using  calibrated  instruments.  Weight  and
eight  of  students  were  measured  with  light  clothes  and
ithout  shoes.  Body  mass  index  (BMI)  was  calculated  as
eight  (kg)  divided  by  the  height  squared  (m2).  Waist  cir-
umference  (WC)  was  measured  using  a  non-elastic  tape
o  the  nearest  0.2  cm  at  the  end  of  expiration  at  the  mid-
oint  between  the  top  of  iliac  crest  and  the  lowest  rib  in
tanding  position.  The  maximum  level  of  hip  without  any
ressure  to  the  body  surface  was  considered  for  measur-
ng  hip  circumference.  Systolic  and  diastolic  blood  pressures
SBP  and  DBP)  were  measured  under  standard  protocol  by
sing  appropriate  cuff  size.  BP  was  measured  twice  after  at
east  ﬁve  minutes  of  rest.  SBP  was  considered  as  the  clear
earing  of  the  ﬁrst  sound  (ﬁrst  Korotkoff  phase)  and  DBP  as
isappearance  of  sound  (ﬁfth  Korotkoff  phase).14
aboratory  tests
or  blood  sampling,  students,  accompanied  by  one  of  their
arents,  attended  the  nearest  health  center  to  their  school
fter  12  h  of  fasting.  Venous  blood  sample  was  obtained
etween  8:00  and  9:30  am  from  the  ante-cubital  vein.  Blood
amples  were  centrifuged  for  10  min  at  3000  rpm,  within
0  min  of  venipuncture.  Fresh  samples  were  analyzed  by
tandard  kits  (Pars  Azmoun,  Tehran,  Iran)  in  the  Central
rovincial  Laboratory,  which  is  under  quality  control  of  the
ational  Reference  Laboratory,  a  World  Health  Organization
WHO)  collaborating  center.
eﬁnition  of  risk  factorshe  International  Diabetes  Federation  (IDF)  deﬁnition  of
etS  for  children  and  adolescents  was  used.15 Overweight
nd  obesity  were  deﬁned  as  BMI  between  85th  and  95th
D
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ercentiles  and  BMI  equal  to  or  higher  than  95th  percentile,
espectively.  WC  above  the  age-  and  gender-speciﬁc  90th
ercentile  was  considered  as  abdominal  obesity.16 Abnor-
al  serum  lipids  were  deﬁned  as  total  cholesterol  (TC),
ow-density  lipoprotein  cholesterol  (LDL-C),  or  triglycerides
TG)  higher  than  the  level  corresponding  to  the  age-  and
ender-speciﬁc  95th  percentile;  or  high-density  lipoprotein
holesterol  (HDL-C)  lower  than  the  age-  and  gender-speciﬁc
th  percentile.17 High  fasting  blood  glucose  (FBG)  was  con-
idered  as  equal  to  or  higher  than  100  mg/dL.16 Mean  SBP
r  DBP  above  the  age-  and  gender-speciﬁc  90th  percentile
as  considered  as  elevated  BP.18 Alanine  aminotransaminase
ALT)  and  aspartate  aminotransaminase  (AST)  were  consid-
red  elevated  if  their  levels  were  at  or  above  the  90th
ercentile  value  calculated  for  children  and  adolescents.19
eﬁnition  of  HW  phenotype
he  HW  phenotype  was  deﬁned  by  the  co-existence  of  WC
bove  the  age-  and  gender-speciﬁc  90th  percentile  and
erum  triglycerides  levels  higher  than  the  age-  and  gender-
peciﬁc  95th  percentile.10
tatistical  analysis
ontinuous  and  categorical  variables  were  expressed
s  means  ±  standard  deviation  (SD)  and  percentages,
espectively.  Independent  t-test  was  used  for  comparing
ontinuous  variables,  and  the  chi-squared  test  was  used  for
ategorical  data.  Binary  logistic  regression  analyses  were
sed  to  evaluate  the  association  of  HW  with  cardiometabolic
isk  factors,  in  each  model,  as  possible  confounders.  Anal-
ses  were  performed  with  SPSS  version  16.0  statistical
ackage  for  Windows  (SPSS  Inc.,  Chicago,  USA).  Two-tailed
-values  were  reported.  p-values  lower  than  0.05  were  con-
idered  as  statistically  signiﬁcant.
esults
n  this  study,  5625  school  students  were  included:  2824
50.2%)  males  and  2801  (49.8)  females,  respectively.  The
ean  age  of  studied  population  was  14.73  ±  2.41  years.
he  prevalence  of  HW  (3%  males  and  3.5%  females)  and  MetS
3%  males  and  5.1%  females)  was  3.3%  and  4%,  respectively.
ixty-nine  (71.1%)  participants  with  HW  had  MetS.
As  some  selected  students  did  not  provide  a  blood  sample
nd  some  biochemical  and  laboratory  measurements  were
ot  performed  properly,  some  cases  were  lost.
Means  and  prevalence  of  anthropometric  variables,  liver
nzymes,  and  cardiometabolic  risk  factors  according  to  gen-
er  and  age  groups,  are  presented  in  Table  1. Mean  levels
f  liver  enzymes,  WC,  SBP,  DBP,  and  FBG  were  signiﬁcantly
igher  in  females  than  in  males  (p  <  0.001).  The  mean  BMI,
otal  cholesterol,  TG,  and  LDL-C  were  signiﬁcantly  higher  in
ales  than  in  females  (p  <  0.001).  The  prevalence  of  MetS,
bdominal  obesity,  elevated  FBG,  high  levels  of  both  SBP  and
BP,  as  well  as  high  levels  of  LDL-C  were  signiﬁcantly  higher
n  females  than  in  males  (p  <  0.05).  The  prevalence  of  over-
eight/obesity  and  hypercholesterolemia  were  signiﬁcantly
igher  in  males  than  in  females  (p  <  0.05).
HW  phenotype,  liver  enzymes  and  cardiometabolic  risk  factors  
Table  1  Frequency  of  cardiometabolic  risk  factors  and
liver enzymes  in  children  and  adolescents  according  to  the
gender:  the  CASPIAN-III  study.
Variables  Males  Females  p-value
Abdominal  obesitya 415  (14.7)  471  (16.9)  0.02
Overweighta 265  (9.4)  186(6.6)  <0.001
Obesitya 286  (10.1)  215  (7.7)  <0.001
High FBGa 278  (12.2)  409  (18.6)  <0.001
High blood  pressurea
Systolic  72  (2.7)  123  (4.8)  0.82
Diastolic  60  (2.2)  114  (4.3)  0.74
Systolic/diastolic  110  (4.2) 190  (7.6)  <0.001
Dyslipidemiaa
High  TC  153  (6.4)  116  (5)  0.03
High TG  188  (8.1)  179  (7.9)  0.82
Low HDL  105  (6.2)  85  (5.3)  0.26
High LDL  667  (33.4)  317  (36.9)  0.02
High liver  enzymesa
ALT  68  (3.5)  76  (3.8)  0.45
AST 136  (6.7)  159  (7.8)  0.11
HW 71  (3.0) 80  (3.5) 0.35
MetS 54(3.0) 87(5.1) 0.02
CASPIAN, childhood and adolescence surveillance and preven-
tion of adult non-communicable disease; BMI, body mass index;
FBG, fasting blood glucose; HW, hypertriglyceridemic waist;
MetS, metabolic syndrome.
a Abdominal obesity: waist circumference above the
age- and gender-speciﬁc 90th percentile; overweight:
85th < BMI < 95th percentile; obesity: BMI ≥ 95th percentile;
high FBG ≥ 100 mg/dL; dyslipidemia, total cholesterol (TC),
low density lipoprotein cholesterol (LDL-C), and triglycerides
(TG), higher than the level corresponding to the age- and
gender-speciﬁc 95th percentile, and/or high-density lipoprotein
cholesterol (HDL-C) lower than the age- and gender-speciﬁc
5th percentile; high blood pressure, systolic and diastolic blood
pressure above the 90th percentile for that age and gender; high
liver enzyme, alanine aminotransaminase (ALT) and aspartate
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Aaminotransaminase (AST) above the 90th percentile value for
Iranian children and adolescents.
Table  2  presents  the  frequency  of  cardiometabolic  risk
factors  and  elevated  liver  enzymes  in  participants  with  and
without  HW  and  MetS  by  gender  and  age  groups.  The  fre-
quency  of  obesity,  elevated  SBP,  htypercholestrolemia,  and
high  levels  of  ALT  were  signiﬁcantly  higher  in  subjects  with
HW  phenotype  and  MetS  than  in  their  peers  (p  <  0.05).
In  Table  3,  the  relationship  of  the  HW  phenotype  with
cardiometabolic  risk  factors  and  liver  enzymes  is  pre-
sented  after  adjustment  for  confounding  variables,  such
as  gender,  socio-economic  status,  parental  education  level,
family  history  of  chronic  diseases,  sedentary  life  style,  and
BMI.  Cardiometabolic  risk  factors  were  deﬁned  according
to  the  Adult  Treatment  Panel  III  (ATP  III)  criteria  modi-
ﬁed  for  children  and  adolescents,  as  follows;  over  weight,
BMI  between  the  85th--95th  percentile;  Obesity,  BMI  >  95th
percentile;  Low  HDL,  <40  mg/dL;  high  LDL,  >130  mg/dL;
high  TG,  ≥150  mg/dL;  high  TC,  >200  mg/dL;  elevated  FBG,
>100  mg/dL;  high  blood  pressure,  >95th  percentile  (adjusted
by  age,  sex,  and  height).
a
p
n515
HW  had  signiﬁcant  association  with  elevated  levels  of
holesterol  and  ALT,  as  well  as  obesity  and  low  HDL-C
p  <  0.05).
iscussion
he  ﬁndings  of  present  study  indicated  that,  in  the  pediatric
ge  group,  the  HW  phenotype  is  associated  with  elevated
evel  of  cholesterol  and  ALT,  as  well  as  obesity  and  low  HDL-
.
Although  the  usefulness  of  HW  phenotype  in  determining
ardiometabolic  risk  factors  has  been  studied  in  previous
tudies  among  adult  population  and  in  different  groups  of
atients,  few  studies  in  this  ﬁeld  were  conducted  in  pedi-
tric  populations.8--10 The  association  of  the  HW  phenotype
ith  elevated  liver  enzymes  was  not  studied  in  any  previous
tudies  in  children  and  adolescents.
Evidence  suggest  that  HW  is  a  simple  clinical  phenotype
hat  represents  excess  visceral  adipose  tissue.  Visceral  fat
ccumulation  is  strongly  associated  with  cardiometabolic
isk  factors  even  in  children.20
HW  is  considered  a  practical  and  simple  tool  that  could  be
sed  as  an  alternative  concept  to  MetS  and  may  be  used  for
creening  high-risk  populations.21 WC  is  an  anthropometric
ndicator  associated  with  some  metabolic  factors,  including
bdominal  obesity,  hyperinsulinemia,  and  increased  levels
f  apolipoprotein.  TG  concentration,  another  component
f  HW,  is  mainly  associated  with  low  HDL-C  and  elevated
DL-C.  High  LDL-C  could  be  predicted  by  hypertriglyceremia
efore  its  manifestation.  An  association  between  hyper-
riglyceridemia  and  presence  of  small  dense  particles  of
DL-C  has  been  suggested.18,22,23
In  this  study,  the  prevalence  of  both  HW  and  MetS  was
nvestigated  in  children  and  adolescents.  In  this  study,  the
revalence  of  HW  was  8.5%.  The  reported  prevalence  rate
f  HW  in  previous  studies  in  the  pediatric  age  group  ranged
etween  6 and  8.5%:  7.3%,  7.2%,  6.4%,  and  8.5%  in  stud-
es  from  the  United  Kingdom,9 Brazil,24 Tehran-Iran,10 and  a
ationwide  study  in  Iran,25 respectively.
Differences  in  lifestyle  habits,  genetic  background,  and
thnicity,  as  well  as  differences  in  laboratory  measurements
ould  explain,  at  least  in  part,  the  various  prevalence  rates
f  HW  in  the  studied  populations.  In  addition,  the  deﬁnition
sed  for  HW  was  not  similar  in  the  abovementioned  studies.
The  ﬁndings  of  the  present  study  indicated  that  approx-
mately  70%  of  adolescent  with  HW  phenotype  fulﬁlled  the
DF  criteria  for  MetS.  As  reported  in  a  previous  study,  ado-
escents  with  the  HW  phenotype  are  more  likely  to  have
etS  and  clustering  of  cardiovascular  risk  factors  than  those
ithout  this  phenotype.10
In  the  present  study,  the  association  between  HW  and
iver  enzymes  among  adolescents  was  investigated  was
nvestigated.  The  results  indicated  that  participants  with
W  had  higher  level  of  ALT  than  those  without  HW.  A  sig-
iﬁcant  association  was  observed  between  HW  phenotype
nd  elevated  ALT.  No  associations  were  observed  between
ST  and  HW  phenotype,  perhaps  because  ALT  is  considered
s  a  better  predictor  of  liver  injury  than  AST,  as  AST  is  also
roduced  in  tissues  other  than  the  liver.26
Several  studies  demonstrated  the  correlation  of  MetS  and
on-alcoholic  fatty  liver  disease  (NAFLD),11,27,28 which  has
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Table  2  Frequency  of  metabolic  risk  factors  and  elevated  liver  enzymes  in  children  and  adolescents  with  and  without  hypertriglyceridemic-waist  and  metabolic  syndrome:
the CASPIAN-III  study.
Males  Males  Females  Females
HW+  HW−  p-value  MetS+  MetS−  p-value  HW+  HW−  p-value  MetS+  MetS−  p-value
10--13.9  years
Overweighta 6  (17.6)  105  (10)  0.14  3  (12)  90  (10.8)  0.85  3  (10.3)  63  (6.2)  0.37  5  (22.7)  45  (5.9)  <0.001
Obesitya 24  (70.6)  106  (10.1)  <0.001  17  (68)  90  (10.8)  <0.001  18  (62.1)  64  (6.3)  <0.001  10  (45.5)  49  (66.5)  <0.001
High FBG  3  (10.3)  132  (12.7)  0.70  7  (28)  86  (10.3)  <0.001  8  (30.8)  169  (17.1)  0.07  13  (59.1)  96  (12.7)  <0.001
High blood  pressurea
Systolic  3  (8.8)  18  (1.8)  <0.001  5  (20)  13  (1.6)  <0.001  1  (3.6)  15  (1.6)  0.43  1  (4.5)  12  (1.6)  0.28
Diastolic 2  (5.9)  15  (1.5)  0.04  3  (12)  11  (1.3)  <0.001  0  (0)  23  (2.4)  0.41  2  (9.1)  16  (2.1)  0.03
Dyslipidemiaa
High  TC  7  (20.6)  58  (5.5)  <0.001  4  (16)  38  (4.6)  <0.001  2  (6.9)  72  (7.1)  0.96  4  (18.2)  47  (6.2)  0.02
Low HDL  13  (54.2)  289  (31.9)  0.02  20  (80)  269  (32.3)  <0.001  12  (48)  259  (29.6)  0.04  19  (86.4)  224  (29.6)  <0.001
High LDL  2  (12.5)  41  (5.5)  0.23  1  (6.2)  39  (5.5)  0.94  1  (5.3)  57  (8.2)  0.64  4  (25)  46  (7.7)  0.01
High liver  enzymesa
ALT  6  (22.2)  36  (4)  <0.001  5  (21.7)  34  (4.6)  <0.001  2  (8)  28  (3.2)  0.19  1  (6.2)  24  (3.5)  0.56
AST 4  (15.4)  70  (7.5)  0.13  3  (13)  56(7.3)  0.30  0  (0)  84  (9.6)  0.11  1  (6.2)  54  (7.9)  0.80
14--18 years
Overweighta 7  (18.9)  104  (8.6)  0.03  6  (20.7)  84  (9.4)  0.04  7  (13.7)  71  (6.1)  0.02  17  (26.2)  47  (5.5)  <0.001
Obesitya 19  (51.4)  94  (7.8)  <0.001  9  (31)  9  (8.8)  <0.001  29  (44.6)  36  (70.6)  <0.001  42  (4.9)  62  (5.3)  <0.001
High FBG  2  (6.5)  140  (12)  0.34  11  (37.9)  77  (8.6)  <0.001  12  (27.9)  208  (18.6)  0.12  35  (53.8)  121  (14.2)  <0.001
High blood  pressurea
Systolic  3  (8.8)  33  (3)  0.05  8  (27.6)  22  (2.5)  <0.001  12  (26.1)  73  (6.7)  <0.001  27  (41.5)  42  (4.9)  <0.001
Diastolic 1  (2.9)  26  (2.3)  0.79  3  (10.3)  17  (1.9)  <0.001  7  (15.2)  68  (6.1)  0.01  19  (29.2)  48  (5.6)  <0.001
Dyslipidemiaa
High  TC  8  (21.6)  79  (6.6)  <0.001  6  (20.7)  53  (5.9)  <0.001  9  (17.6)  31  (2.7)  <0.001  9  (13.8)  16  (1.9)  <0.001
Low HDL  13  (54.2)  60  (6.8)  0.82  5  (20)  45  (6.2)  <0.001  20  (44.4)  434  (43.1)  0.85  51  (78.5)  361  (42.2)  <0.001
High LDL  2  (8)  349  (34)  0.04  28  (96.6)  304  (33.9)  <0.001  2  (6.5)  23  (2.8)  0.23  3  (5.5)  20  (2.5)  0.27
High liver  enzymesa
ALT  1  (4.3)  25  (2.4)  0.54  1  (3.8)  24  (3)  0.79  8  (17.8)  35  (3.3)  <0.001  10  (16.14)  26  (3.3)  <0.001
AST 1  (4.3)  61  (5.7)  0.75  2  (7.4)  47  (5.7)  0.70  3  (6.4)  71  (6.7)  0.83  3  (5)  48  (6)  0.74
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Table  2  (Continued)
Males  Males  Females  Females
HW+  HW− p-value MetS+  MetS− p-value HW+  HW− p-value MetS+  MetS− p-value
10--18  years
Overweighta 13  (18.3) 409  (18.1) 0.01 9  (16.7) 174  (10.1) 0.11 10  (12.5) 134  (6.1) 0.02 22  (24.4) 92  (5.6) <0.001
Obesitya 43  (60.6) 200  (8.9) <0.001 26  (48.1) 169  (9.8) <0.001 54  (67.5) 126  (5.8) <0.001 52  (25.7) 111  (36.2) <0.001
High FBG 5  (8.3) 272  (12.3) 0.35 18  (33.3) 163  (9.4) <0.001 20  (29) 377  (17.9) 0.01 48  (55.2) 217  (13.5) <0.001
High blood  pressurea
Systolic  6  (8.8) 51  (2.4) <0.001 13  (24.1) 35  (2) <0.001 13  (17.6) 88  (4.4) <0.001 28  (32.2) 24  (3.2) <0.001
Diastolic 3  (4.4)  41  (1.9)  0.14  6  (11.1)  28  (1.6)  <0.001  7  (9.6)  91  (6.4)  0.03  21  (24.1)  64  (4)  <0.001
Dyslipidemiaa
High  TC 15  (21) 137  (6.1) <0.001 10  (18.5)  91  (5.3)  <0.001  11  (13.8)  103  (4.7)  <0.001  13  (14.9)  63  (3.9)  <0.001
Low HDL  26  (54.2)  638  (33)  <0.001  48  (88.9)  73  (33.1)  <0.001  32  (45.7)  693  (36.8)  0.12  70  (80.5)  585  (36.3)  <0.001
High LDL  4  (9.8)  101  (6.2)  0.35  6  (14.6)  84  (6)  0.02  3  (6)  80  (5.2)  0.81  7  (9.9)  66  (5.1)  0.07
High liver  enzymesa
ALT  7  (14)  61  (3.1)  <0.001  6  (12.2)  58  (3.7)  <0.001  10  (14.3)  63  (3.3)  <0.001  11  (14.3)  50  (3.4)  <0.001
AST 5  (10)  131  (6.5)  0.32  5  (10)  103  (6.5)  0.32  3  (4.2)  155  (8)  0.24  4  (5.3)  102  (6.9)  0.58
CASPIAN, childhood and adolescence surveillance and prevention of adult non-communicable disease; BMI, body mass index; FBG, fasting blood glucose; HW, hypertriglyceridemic waist;
MetS, netabolic syndrome.
a Overweight: 85th < BMI < 95th percentile, obesity: BMI ≥ 95th percentile; dyslipidemia: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) higher
than the level corresponding to the age- and gender-speciﬁc 95th percentile, and/or high density lipoprotein cholesterol (HDL-C) lower than the age- and gender-speciﬁc 5th percentile;
elevated blood pressure: systolic and diastolic blood pressure above the 90th percentile for that age and gender; elevated liver enzyme, alanine aminotransaminase (ALT) and aspartate
aminotransaminase (AST) above the 90th percentile value for Iranian children and adolescents.
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Table  3  Association  of  cardiometabolic  risk  factors  with  hypertriglyceridemic-waist  in  logistic  regression  model:  the  CASPIAN-III
study.
Cardiometabolic  risk  factorsa HW
Crude  model
OR  (95%CI)
Adjusted  modelb
OR  (95%CI)
MetS  113.46  (68.99--186.57)c 64.24  (30.55--135.06)
Obesity 22.66  (15.94--32.20)c 23.11  (14.84--35.98)c
Overweight  2.14  (1.35--3.39)c 1.57  (0.84--2.93)
High TC 3.62  (2.32--5.63)c 2.17  (1.11--4.21)c
High  LDL 1.36  (0.62--2.99) 0.83  (0.23--3.00)
High ALT 4.99  (2.9--8.59)c 0.88  (0.28--2.70)
High AST 0.90  (0.43--1.87) 0.56  (0.18--1.69)
High blood  pressure  3.09  (1.90--5.02)c 1.21  (0.60--2.46)
High FBG  1.35  (0.86--2.11)  1.12  (0.60--2.08)
CASPIAN, childhood and adolescence surveillance and prevention of adult non-communicable disease; FBG, fasting blood glucose; TC,
total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine aminotransaminase; AST, aspartate amino-
transaminase; HW, hypertriglyceridemic waist; MetS, metabolic syndrome.
a Cardiometabolic risk factors according to Adult Treatment Panel III (ATP III) criteria modiﬁed for children and adolescents: over
weight, BMI between the 85th and 95th percentile; obesity, BMI > 95th percentile; low HDL, <40 mg/dL, high LDL, >130 mg/dL; high TC,
>200 mg/dL; high FBG, >100 mg/dL; high blood pressure, >95th percentile (adjusted by age, sex, height).
b Adjusted for age, gender, socio-economic status, parental educations, family history of chronic diseases, sedentary life style, and
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c Statistically signiﬁcant.
ecently  become  as  an  important  health  problem  in  the
ediatric  population.28 Elevated  liver  enzymes  are  usually
sed  as  a  non-invasive  method  to  detect  cases  with  NAFLD.
indings  of  studies  in  Iran  and  other  regions  conﬁrmed  a
igniﬁcant  association  between  elevated  liver  enzymes  and
ardiometabolic  risk  factors  among  children  and  adoles-
ents.  These  studies  proposed  that  elevated  ALT  and  AST
ould  be  considered  as  a  cardiometabolic  risk  factor  and
n  additional  component  of  the  MetS  in  the  pediatric  age
roup.11,27,29,30 The  results  of  the  present  study  could  serve
s  conﬁrmatory  evidence  for  such  suggestion.
These  ﬁndings  are  also  consistent  with  a  previous  study
hat  indicated  a  signiﬁcant  relationship  between  elevated
LT  and  cardiometabolic  risk  factors  and  HW  phenotype
mong  6--18-year-old  students.11,24
In  the  present  study,  adolescents  with  HW  phenotype  had
igher  frequency  of  overweight/obesity,  as  well  as  elevated
BP  and  total  cholesterol.  Elevated  FBG  and  DBP  were  more
revalent  in  females  with  HW  phenotype  than  in  other  par-
icipants;  whereas  low  HDL-C  was  more  prevalent  among
ales  with  HW  phenotype.
After  adjustment  for  age,  females  with  HW  pheno-
ype  were  more  likely  to  have  high  cholesterol,  high  FBG,
levated  BP,  MetS,  obesity,  and  elevated  ALT.  Further  adjust-
ent  for  factors  including  socio-economic  status,  parental
ducation,  family  history  of  chronic  diseases,  and  seden-
ary  lifestyle  showed  that  females  with  HW  phenotype  were
ore  likely  to  have  overweight/obesity,  MetS,  elevated  BP,
nd  increased  ALT.
After  adjustment  for  age,  males  were  more  likely  to  have
igh  cholesterol,  elevated  BP,  MetS,  obesity,  and  elevated
LT.  With  additional  adjustment  for  the  abovementioned
onfounding  factors,  male  were  more  likely  to  have  high
holesterol  and  MetS.
r
a
UDespite  the  limited  experience  on  the  performance  of  HW
henotype  in  identifying  cardiometabolic  risk  factors  among
hildren  and  adolescents,  some  recent  studies  have  inves-
igated  such  relationship.  Bailey  et  al.  have  evaluated  the
ssociation  between  HW  and  cardiometabolic  disorders  in
34  adolescents  aged  10--19  years  in  the  United  Kingdom.
hey  indicated  that  adolescents  with  HW  had  higher  lev-
ls  of  cholesterol,  FBG,  and  DBP,  as  well  as  lower  level  of
DL-C,  than  those  without  HW.  In  their  study,  participants
ith  HW  phenotype  had  higher  mean  scores  for  clustered
ardiometabolic  risk  scores.  Adolescents  with  HW  pheno-
ype  were  at  higher  risk  for  low  HDL-C,  impaired  fasting
lucose,  and  >one  and  >two  cardiometabolic  risk  factors
ncluding  hypercholesterolemia,  low  HDL-C,  elevated  SBP  or
BP,  and  impaired  FBG  than  those  without  this  phenotype.
hese  authors  concluded  that  HW  could  be  a  simple  marker
or  identifying  children  and  adolescents  who  are  at  high  risk
or  cardiometabolic  risk  factors.9
Conceic¸ão-Machado  et  al.  have  investigated  the  preva-
ence  of  HW  and  its  association  with  metabolic  abnormalities
n  1076  Brazilian  adolescents  aged  11--17  years.  Accordingly,
dolescents  with  HW  phenotype  had  higher  level  of  obesity,
on-HDL  cholesterol  and  LDL-C  than  those  without  it.  These
uthors  reported  a  signiﬁcant  association  between  the  HW
henotype  and  atherogenic  lipid  proﬁle.  They  did  not  ﬁnd
ny  association  between  FBG  and  HW  phenotype.24
A  study  among  Tehranian  adolescents  demonstrated  that
W  phenotype  was  associated  with  hyperlipidemia  and  ele-
ated  BP,  but  not  with  FBG.10
The  present  results  regarding  the  lack  of  association
etween  HW  phenotype  and  FBG  are  consistent  with  those
23 10eported  in  Brazil and  Iran. However,  they  are  not  in
greement  with  the  results  of  the  study  conducted  in  the
nited  Kingdom.8 The  observed  results  may  be  due  to  the
ors  
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1HW  phenotype,  liver  enzymes  and  cardiometabolic  risk  fact
differences  in  dietary  habits  and  ethnicity  in  the  studied
populations.
The  ﬁndings  of  the  present  study  are  in  line  with  the
previous  nationwide  study  by  the  authors,  which  indicated
a  higher  rate  of  hyperlipidemia  among  adolescents  with  HW
phenotype.24 These  ﬁndings  suggest  that  the  HW  phenotype
could  be  used  as  a  simple  screening  tool  for  identiﬁcation  of
high-risk  children  and  adolescents.
The  main  limitation  of  the  current  study  was  its  cross-
sectional  nature.  In  addition,  itw  as  not  possible  to
determine  the  pubertal  stage  of  participants,  and  because
of  the  effects  of  puberty  on  lipid  proﬁle,  especially  among
boys,  the  number  of  subjects  with  hypertriglyceridemia
could  be  overestimated.31
Another  limitation  was  the  missing  data  =  for  each  vari-
able;  however,  as  presented  in  the  tables,  the  number  of  the
missing  data  was  only  one.
The  main  strength  of  this  study  was  the  large,  nationwide
sample  of  a  pediatric  population.  However,  in  spite  of  the
large  sample  studied,  the  number  of  participants  with  HW
and  or  MetS  was  low;  without  considering  this  large  number
of  participants,  an  appropriate  sample  size  of  children  and
adolescents  with  HW  or  MetS  would  not  have  been  reached.
Future  studies  with  larger  number  of  participants  with  such
disorders  would  reach  more  generalizable  results.
The  other  strengths  were  using  the  age-  and  sex-speciﬁc
percentiles  for  WC  and  TG  levels,  as  well  as  studying  liver
enzymes  in  addition  to  cardiometabolic  risk  factors.
The  ﬁndings  of  the  present  study  suggest  that  the  HW
phenotype  could  be  used  as  a  screening  tool  for  iden-
tifying  children  at  high-risk  for  elevated  ALT  and  some
cardiometabolic  risk  factors.  Due  to  its  simplicity,  low  cost,
and  usefulness,  HW  can  be  used  in  primary  care  settings  and
large  epidemiological  studies  instead  of  measuring  all  MetS
components.  Further  longitudinal  studies  are  necessary  to
verify  the  clinical  implications  of  the  present  ﬁndings.
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